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Introduction: Although Alzheimer’s disease (AD) is associated with early death, its life expectancy differs greatly
between patients. A better understanding of this heterogeneity may reveal important disease mechanisms
underlying the malignancy of AD. The aim of this study was to examine the relation between AD pathologies and
early death in AD caused by dementia.
Methods: At a memory clinic, 247 referred consecutive patients with AD were monitored during 12.6 ± 1.6 years.
Multivariate Cox regression analyses were performed with baseline measures of amyloid beta (Aβ) pathology
(APOE genotype, cerebrospinal fluid (CSF) Aβ42) tau pathology (CSF phosphorylated tau and total tau),
cerebrovascular pathology (white-matter lesions and CSF/serum albumin ratio), neuroinflammatory pathology
(CSF soluble vascular cell adhesion molecule-1, sVCAM-1), frontal, temporal, and central brain atrophies, global
cognition, sex, and age. Comorbidities and medications also were analyzed. All continuous variables were
transformed to z scores to compare hazard ratios (HRs) and 95% confidence intervals (CIs).
Results: At follow-up, 89% of the patients had died. The mean survival time was 6.4 ± 3.0 years. The AD pathology
that independently predicted an early death caused by dementia was cerebral inflammation (sVCAM-1; HR, 1.32;
95% CI, 1.07–1.64). Other independent predictors were lower global cognition (HR, 0.51; 95% CI, 0.43–0.61), frontal
atrophy (HR, 1.38; 95% CI, 1.12–1.70), and medial temporal atrophy (HR, 1.23; 95% CI, 1.02–1.49). When examining
death caused by dementia and related causes (vascular diseases and infections), age (HR, 1.23; 95% CI, 1.04–1.46)
and cerebrovascular pathology (white-matter lesions: HR, 1.17; 95% CI, 1.01–1.36; and CSF/serum albumin ratio: HR,
1.16; 95% CI, 1.001–1.34) were also significant risk factors in addition to the previous variables. No comorbidity or
medication was significant in the specific-cause models.
Conclusions: This is the first study to link neuroinflammation independently to early death in AD and, hence, a
rapidly progressing disease. Frontal and medial temporal atrophies and low cognition were also significant
predictors. These are probably downstream biomarkers that reflect neuronal degeneration and late-stage disease.
Our results suggest that inflammation, and not amyloid or tau pathology, is an independent underlying mechanism
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Alzheimer’s disease (AD) is strongly associated with an
early death, compared with the nondemented elderly
population [1-5]. Recent data from the United States
showed that AD accounts for a population-attributable
risk between 5% and 15% on 5-year mortality for ages 65
and older, and represents the fifth leading cause of death
in the same age range [6]. Even when adjusting for other
diseases that are commonly regarded as causes of death,
such as cancer or cardiac diseases, AD remains an inde-
pendent risk factor for early death [7,8]. The survival from
the time of AD diagnosis varies between 3 and 8 years
[9,10]. Pneumonia is the most common cause of death in
AD in studies using death certificates [11], medical records
from the institution where the patient died [12], and studies
based on autopsy for the determination of cause of death
[13]. However, pneumonia can be considered merely a
“symptom” caused by deteriorated health status, dysphagia,
malnutrition, or problems with clearing secretions, which
is seen in end-stage dementia [11,13-15]. The question,
which has been stated before [7], is what mechanisms or
pathologies drive the disease rapidly to this end-stage to a
greater extent in some patients than in others. A better
understanding of the heterogeneity of the life expectancy
in AD may highlight important pathologic mechanisms of
the malignancy of AD and provide a more accurate prog-
nosis for patients.
AD is associated with different brain pathologies, such
as amyloid beta deposition, tau pathology, vascular le-
sions, and cerebral inflammation [16-18]. The combin-
ation of these pathologies differs among patients and
can probably explain some of the heterogeneity observed
within the spectrum of AD symptoms [19]. Our aim in
the present study was to examine whether a certain
combination of these pathologies, or the prominence
of a specific pathology, can explain the huge difference
in life expectancy observed in AD. Therefore, we inves-
tigated the predictive ability of AD pathologies and re-
lated factors regarding mortality.
Methods
Subjects
The patients originated from the Malmö Alzheimer
Study [20]. This study consisted of consecutive patients
who were referred to the Memory Clinic of the Skåne
University Hospital in Malmö, Sweden, because of cognitive
complaints. Patients who underwent a lumbar punc-
ture (which was part of the clinical routine) and were
diagnosed with probable or possible AD [21] between
1999 and 2003 were included. Physicians with experi-
ence in dementia disorders assessed the patients, who
underwent computed tomography (CT) or magnetic
resonance imaging (MRI) of the brain, lumbar puncture,
cognitive tests, and blood analysis.The Malmö Alzheimer Study consisted of 259 patients.
Of these, 12 were excluded from the present study because
of missing data; the current study population included 247
patients with a complete data set.
The patients gave their consent for research, and the
study was approved by the Regional Ethics Committee in
Lund (2012/461 and 2010/401) and the Swedish National
Board of Health and Welfare (58744/2012).
Mortality data
The follow-up consisted of a control whether the patient
was alive or not in April 2013, and the follow-up time
was defined as the duration from the CT/MRI scan to
this control. If the patient was dead, the specific cause of
death was obtained from the Swedish Causes of Death
Register. The cause of death was determined mostly
clinically by an attending responsible physician with
knowledge of the patient’s medical history, and, in only
a few cases, by autopsy. The causes were specified accord-
ing to the 10th revision of the International Classification
of Disease (ICD-10) [22]. To examine better the patholo-
gies of AD that increase mortality specifically related to
AD, the causes of death were divided into three groups
based on the diagnoses in the death register.
Dementia
These causes were not restricted to AD (although this was
the initial diagnosis), but also included vascular dementia
and unspecified dementia (ICD F01, F03, and G30), as
some patients acquired other brain pathologies during the
time of the study. In these cases, the patient had no other
apparent diseases that could have caused death.
Dementia and related causes
In addition to the causes described, this group
consisted of cerebrovascular diseases, heart disease, and
other vascular diseases; ICD I2X, I4X–I7X), which are
risk factors for AD and share the feature of vascular
pathology. Infections (most commonly pneumonia,
but also infections related to decubitus and unknown
infections) were also included in this group (ICD A41,
J18, N39), because aspiration, self-neglect, and
sedentary lifestyle are very common consequences of
late-AD symptoms.
All-cause mortality
This group consisted of all available causes of death
including those not related to dementia, such as cancer,
gastrointestinal diseases, and chronic obstructive
pulmonary disease (COPD).
Risk factors for mortality: main analysis
The potential risk factors for mortality were chosen based
on the known pathologies and biomarkers of AD, and
constituted the main analysis. Only baseline variables were
used in the study. They were as follows:
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The 42-amino-acid isoform of amyloid-β1–42 (Aβ42) in
cerebrospinal fluid (CSF) was analyzed with Luminex
xMAP technology to assess amyloid burden [23]. The
procedures and analysis of the lumbar puncture and
CSF analysis followed the Alzheimer’s Association Flow
Chart [24]. Another variable that is associated with
amyloid deposition is the apolipoprotein E (APOE) ε4
allele, especially the presence of two alleles. APOE was
therefore entered into the model as a dichotomous
variable (that is, presence or absence of ε4/ε4).
Tau pathology
The levels of total tau and tau phosphorylated at Thr181
(P-tau) in the CSF were determined to examine tau
pathology. They were analyzed by using the same method
as that used to assess Aβ42.
Cerebrovascular pathology
White-matter lesions in the left and right frontal and
parietal-occipital regions, as well as lesions in the left
and right basal ganglia, were assessed by using the
Age-Related White Matter Changes (ARWMC) scale
[25]. The assessment was performed by S.P. by using
CT or MRI scans. The specific procedures, as well as
intra- and interrater reliability of this method were pub-
lished previously [26]. The scores from the different re-
gions were added to obtain a combined score ranging
from 0 to 18 points. In addition to the ARWMC scale,
the CSF/serum albumin ratio (albumin ratio), which is a
marker for the integrity of the blood–brain barrier (BBB),
also was calculated.
Neuroinflammatory pathology
The CSF levels of the soluble vascular cell-adhesion
molecule 1 (sVCAM-1) were analyzed as a measure of
cerebral inflammation by using a commercially avail-
able quantitative enzyme-linked immunosorbent assay
(ELISA) kit (R&D Systems, Minneapolis, MN, USA).
This procedure was described previously [20].
Regional atrophy
Atrophy is, per se, not a pathologic process, but a bio-
marker of neuronal degeneration, which is a hallmark
of AD. Different cerebral areas are affected in AD, depend-
ing on disease type and duration [27]. Atrophy was assessed
by an experienced radiologist (Y.Z.) by using linear mea-
surements on CT or MRI scans. To include the essential
brain regions, the following measures were entered into a
Cox regression model: (a) the temporal horn ratio, which
measures medial temporal atrophy, (b) Evans ratio, which
measures frontal atrophy, and (3) the cella media index,
which measures central atrophy. The details of this
procedure were published previously [28].Cognition, sex, and age
The Mini-Mental State Examination (MMSE) was used
to assess global cognitive function [29]. In addition, sex
and age were entered in the models, as both of these
characteristics might affect the other independent vari-
ables and mortality.
Concomitant diseases and medications: subanalyses
Concomitant diseases and medications are potentially
influential risk factors for the prediction of mortality
caused by AD pathology. These variables were not
included in the main Cox regression analysis because of
their high number. Instead, they were analyzed in separ-
ate Cox regression models. Data on current medications
and comorbidities were collected from information pro-
vided by patients and their relatives and from documen-
tation on diseases and drugs in the patients’ medical
records. Several diseases were grouped in larger categories;
ischemic heart disease, congestive heart failure, and ar-
rhythmias were named “heart diseases”; all gastrointestinal
diseases were grouped together, as well as all pulmonary
diseases. Finally, liver and kidney diagnoses were grouped
together in one category. Diagnoses with a frequency
smaller than 5% were called “all other diseases.”
Current medications were grouped together based on
mechanism or treatment indication, except for the category
cardiovascular drugs, which included all heart-disease indi-
cations and antihypertensive treatment, as these often co-
occur, and could not be distinguished from each other.
Statistics
Cox proportional hazards models were used to estimate
separately the effects of the previously mentioned risk
factors on the relative risk of time to death (caused by
dementia, dementia and related causes, and all-cause
mortality). All continuous variables followed a normal
distribution and were screened for collinearity by using
Pearson correlation; the highest correlation coefficient
was seen between tau and P-tau (r = 0.77). To facilitate the
comparison of hazard ratios (HRs) in the Cox regression
analysis, all continuous variables were converted to z
scores in the main analyses. Thus, the HR corresponded
to an increase of 1 standard deviation (SD). This conver-
sion does not affect the model or the significance values of
the covariates.
The dichotomous variables were entered into the model
if their prevalence was at least 10%, to avoid unstable esti-
mates and a diminished statistical power. This approach
did not affect the main analysis, but excluded the follow-
ing potential predictors from the subanalyses: diabetes,
major depression, liver/kidney disease, and medication
with antacids, NSAIDs, or hormone therapy. The duration
from the date of CT/MRI scan to either death or follow-
up (that is, controlling whether the patient was deceased)
Figure 1 Cause of death. Sixty-five different ICD-10 codes were
found on the death certificates. These have been grouped into these
11 categories.
Table 2 Prevalence of concomitant diseases and medications
Disease category Prevalence (%)
Folate or vitamin B12 deficiency 41
All other diseases 39
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were entered by using the stepwise backward likelihood
ratio (LR) method with an entry limit of P = 0.05 and a re-
moval limit of P = 0.051, to avoid including nonsignificant
variables in the final model. All analyses were performed
with SPSS (IBM Corp. Released 2011. IBM SPSS Statistics
for Mac, Version 20.0. Armonk, NY, USA).
Results
Demographics
The demographics of, and variables analyzed in all 247
patients are shown in Table 1. The mean follow-up time
(that is, from CT/MRI scan until the follow-up) was 12.6
years (SD, 1.6 years). At follow-up, 221 (89%) of the 247
patients had died. The mean time to death was 6.4 years
(SD, 3.0 years). The causes of death were specified by
65 different ICD-10 codes. These were grouped into 11
different categories (Figure 1). The most common
cause was dementia (55%), which was interpreted as an
absence of other apparent diseases that could have
caused death. Different cerebrovascular, cardiovascular,
and other vascular causes of death were the second largest
group (23.1%). Infections and cancer were the causes of
death in 6.4% and 5.9% of the cases.
The concomitant diseases and medications are shown
in Table 2. Folate or vitamin B12 deficiency was the
most common diagnosis (41%), followed by hypertension
(32%), gastrointestinal diseases (30%), and heart disease
(26%). The most common drugs were antidepressants (43%),Table 1 Characteristics (variables entered into the Cox
Regression Analysis)
Variable Mean ± SD
(n = 247)
Time to death, n = 221 (years) 6.4 ± 3.0
Age (years) 75.2 ± 6.1
Sex (female) 69%
MMSE score (0 to 30 points) 21.3 ± 5.1
Temporal horn ratio (medial temporal atrophy) 0.040 ± 0.017
Evans ratio (frontal atrophy) 0.33 ± 0.038
Cella media index (central atrophy) 0.22 ± 0.040
CSF sVCAM-1 (neuroinflammatory pathology, μg/L) 11.7 ± 4.3
ARWMC (cerebrovascular pathology, 0 to 18 points) 3.2 ± 3.4
Albumin ratio (BBB integrity) 0.0075 ± 0.0032
CSF Tau (pg/ml) 619 ± 322
CSF P-tau (pg/ml) 76 ± 31
CSF Aβ42 (pg/ml) 410 ± 99
APOE ε4/ε4 22%
Aβ, beta-amyloid; APOE, apolipoprotein E; ARWMC, Age-Related White Matter
Changes scale; BBB, blood–brain barrier; CSF, cerebrospinal fluid; MMSE, the
Mini-Mental State Examination; SD, standard deviation; sVCAM-1, soluble
vascular cell adhesion molecule-1.followed by cardiovascular drugs (34%) and antipsychotics/
sedatives (31%).
Prediction of mortality: main analyses
The significant variables for predicting death caused







Major depression or anxiety disorders 9
Diabetes 8






Analgesics (except aspirin and NSAIDs) 13
Thyroxine 12




NSAIDs, nonsteroidal antiinflammatory drugs.
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sVCAM-1 (HR, 1.32; 95% CI, 1.07–1.64), and temporal
horn ratio (HR, 1.23; 95% CI, 1.02–1.49), which are shown
in Table 3 (that is, the independent risk factors for death
caused by AD were frontal and medial temporal atrophy,
high levels of cerebral inflammation, and, most significantly,
low cognitive status at baseline). Note that all HRs are
based on z scores, which allows a head-to-head comparison
of the HRs of the variables.
When predicting dementia- and AD-pathology-related
causes of death, the significant variables were Evans ratio
(HR, 1.33; 95% CI, 1.13–1.57), sVCAM-1 (HR, 1.22; 95% CI,
1.03–1.45), albumin ratio (HR, 1.16, 95% CI, 1.001–1.34),
ARWMC score (HR, 1.17; 95% CI, 1.01–1.36); MMSE score
(HR, 0.58; 95% CI, 0.50–0.66), and age (HR, 1.23; 95% CI
1.04–1.46) (Table 3). In addition to frontal atrophy, cerebral
inflammation, and cognitive impairment, this model found
that cerebrovascular pathology and older age were signifi-
cant independent predictors for death caused by dementia
and related causes. This was probably caused by the vascu-
lar origin of most of the AD-related causes of death.
The model for all-cause mortality revealed the fol-
lowing significant variables: Evans ratio (HR, 1.31; 95% CI,
1.13–1.52), age (HR, 1.28; 95% CI, 1.10–1.49), MMSE score
(HR, 0.59; 95% CI, 0.52–0.67), and sVCAM-1 (HR, 1.24;
95% CI, 1.07–1.45) (Table 3).Table 3 Risk factors for AD mortality (multivariate Cox
regression analyses)
Cause of death Significant variables P value HR (95% CI)
Dementia Cognition <0.001 0.51 (0.43–0.61)
Frontal atrophy 0.003 1.38 (1.12–1.70)






Cognition <0.001 0.58 (0.50–0.66)
Frontal atrophy <0.001 1.33 (1.13–1.57)
Age 0.019 1.23 (1.04–1.46)
Inflammation 0.024 1.22 (1.03–1.45)
Vascular lesions 0.036 1.17 (1.01–1.36)
BBB integrity 0.048 1.16 (1.001–1.34)
All-cause mortality Cognition <0.001 0.59 (0.52–0.67)
Frontal atrophy <0.001 1.31 (1.13–1.52)
Age 0.001 1.28 (1.10–1.49)
Inflammation 0.005 1.24 (1.07–1.45)
All variables described in Risk factors of mortality (Methods) were entered into
each of the three models. The continuous variables were converted to z
scores. Only significant variables are shown in the table. The following
variables were not significant in any of the models: CSF Aβ42 and APOE ε4/ε4
(amyloid pathology), CSF tau and P-tau (tau pathology), cella media index
(central atrophy), and sex. BBB integrity, CSF/serum albumin ratio; cognition,
MMSE score; CI, confidence interval; frontal atrophy, Evans ratio; HR, hazard
ratio; inflammation, sVCAM-1; medial temporal atrophy, temporal horn ratio;
vascular lesions, ARWMC (Age-related White Matter Changes scale).The variables for amyloid (Aβ42 and APOE ε4/ε4) and
tau (total tau and P-tau) pathology were not significant
in any of the models (data not shown).
The effect of comorbidity and medications: subanalyses
No concomitant disease was a risk factor for death caused
by dementia (Table 4). Neither could a concomitant disease
predict death caused by dementia and related causes; how-
ever, older age was a significant risk factor in this model
(HR, 1.04; 95% CI, 1.02–1.07). When predicting all-cause
mortality, both older age (HR, 1.04; 95% CI, 1.02–1.07) and
hypertension (HR, 1.34; 95% CI, 1.01–1.78) were significant
variables (Table 4).
Similarly, no medications were risk factors for death
caused by dementia (Table 4), and older age was a signifi-
cant risk factor for death caused by dementia and related
causes (HR, 1.04; 95% CI, 1.02–1.07). In the all-cause model,
the following variables were significant (Table 4): older
age (HR, 1.04; 95% CI, 1.02–1.06), antipsychotics/sedatives
(HR, 1.36; 95% CI, 1.02–1.82), and cardiovascular drugs
(HR, 1.38; 95% CI, 1.04–1.83).
Discussion
In this 13-year longitudinal study of 247 patients with
mild-to-moderate AD, we found that increased cerebral
inflammation was the only AD-related pathology that
was an independent risk factor for death caused specifically
by dementia (Table 3). Other significant risk factors were
low cognitive ability, frontal atrophy, and medial temporal
lobe atrophy. Tau, amyloid, or cerebrovascular pathology
were not significant variables in the Cox regression model
for death caused by dementia.
To the best of our knowledge, the present study is the
first to show that cerebral inflammation is independently
associated with early death in AD. Cerebral inflammation,
as measured by CSF sVCAM-1 level, was a risk factor for
early death in all mortality groups (Table 3). Previous
studies reported that neuroinflammation is involved in the
pathogenesis of AD [18,30-33]. It has been suggested that
chronic neuroinflammation represents a risk factor for
AD in the elderly through an acceleration of senescence in
microglia, with a reduction in their neuroprotective
function leading to the formation of senile plaques and
neurofibrillary tangles [34]. A recent neuropathologic
study found that cerebral inflammation measured as
glial response is an essential mechanism that determines
which of the patients with a high load of tau and amyloid
pathology were demented or nondemented [19]. Thus,
inflammation might be a key component in the toxicity of
β-amyloid, as many individuals have a high burden of
amyloid and tau pathology without any clinical symptoms
[19]. Furthermore, Forassi et al. [35] showed that systemic
inflammation is a strong independent risk factor for death
in an elderly population.
Table 4 Comorbidity and medication risk factors for mortality (multivariate Cox regression analyses)
Risk factors (covariates) Cause of death (dependent variable) Significant variables P value HR (95% CI)
Comorbidities Dementia No significant variables
Dementia and related causes Age <0.001 1.31 (1.12–1.53)
All-cause mortality Age <0.001 1.30 (1.13–1.50)
Hypertension 0.041 1.34 (1.01–1.78)
Medications Dementia No significant variables
Dementia and related causes Age <0.001 1.30 (1.11–1.52)
All-cause mortality Age 0.001 1.27 (1.10–1.47)
Cardiovascular drugs 0.024 1.38 (1.04–1.83)
Antipsychotics/sedatives 0.036 1.36 (1.02–1.81)
Age was converted to a z-score for comparison with the continuous variables shown in Table 3. All comorbidities and medications with a prevalence ≥10%
(Table 2), as well as age and sex, were entered into the Cox regression analyses. Comorbidities and medications were entered separately. HR, hazard ratio.
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cognitive status, frontal atrophy, and medial temporal
lobe atrophy) should probably be interpreted as down-
stream biomarkers, which reflect the disease duration
and disease stage. Other studies have also found that
low cognitive function and atrophy at baseline are sig-
nificant risk factors for mortality [36-39]. Frontal atro-
phy was a stronger predictor than medial temporal
atrophy (Table 3), possibly because medial temporal at-
rophy is an earlier step in the disease process, whereas
frontal atrophy occurs later, as an indicator of end-stage de-
mentia [27]. Another explanation could be that AD patients
with frontal lobe degeneration constitute a subset of AD
with a more rapid disease progression. This assumption
is supported by previous results, that revealed that tests
of frontal cognitive function, but not those of parietal
and temporal function, independently predicted a more
rapid AD progression [40].
The results of the subanalyses showed that AD-related
factors, but not concomitant diseases or medications,
caused early death in AD (Table 4). This was further
supported by the fact that neither older age nor male
sex predicted specific-cause death (Table 4), even though
they are regarded as traditional predictors of death among
elderly individuals.
Neuroleptic/sedative drugs were associated with early
death in the all-cause model, which was in line with pre-
vious studies that showed that psychotic symptoms and/
or neuroleptic drugs increase mortality rates [4,41,42].
The mean survival time of 6.4 years found here was in
agreement with a large review of 42 studies on AD mor-
tality [43]. Large differences are found in the prevalence
of death causes, but overall, pneumonia and dementia
have been reported most commonly [3,11,13,44], which
differs somewhat from the results of the present study
(Figure 1). We believe this can be explained by the man-
ner in which the cause of death was entered on the
death certificate, rather than by an actual difference in
death causes. If no other specific diagnosis was apparentat the time of death, the attending physician most likely
regarded dementia as the cause of death.
One of the strengths of this study was that it constitutes
the world’s longest longitudinal study with CSF biomarkers
of AD, which ensures a high diagnostic accuracy and a low
number of censored cases (patients still alive at follow-up).
We also examined predictors of specific-cause death due to
dementia, and not only all-cause death, which is essential
when trying to map key mechanisms of mortality in AD.
Other advantages of our study included the multivariate
design of the analysis, which allowed us to examine in-
dependent effects of the most common pathologies and
hallmarks of AD, and the inclusion of patients from a
routine clinical setting.
We chose to measure cerebral inflammation by using
sVCAM-1 levels in the CSF, based on previous validating
studies [45-50]. sVCAM-1 is a cell-surface molecule that
regulates leukocyte migration and is activated by proin-
flammatory factors such as cytokines and interleukins
[49]. Moreover, it has been associated with glial activation
(expressed on astrocytes) [47]. Numerous studies have
associated increased levels of sVCAM-1 with several
neuroinflammatory conditions, and it has been significantly
correlated with inflammatory cerebral lesions assessed
by using contrast MRI [45-50]. sVCAM-1 is also a well-
proven marker of endothelial dysfunction and has been
associated with atherosclerosis [51] and small-vessel disease
[52]. However, based on our results, we believe that
sVCAM-1 is related more directly to neuroinflammation,
rather than to cerebrovascular pathology, as sVCAM-1, not
vascular lesions and BBB integrity, was an independent
significant variable in the main analysis performed to
predict death caused by dementia (Table 3). Vascular le-
sions and BBB integrity were, however, separately signifi-
cant when examining death also caused by cerebrovascular
disorders, which validates them as adequate markers of vas-
cular pathology in this data set.
To warrant our conclusions, the results of this explora-
tory study should be tested in larger longitudinal cohorts
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survival (for example, diabetes) and using other markers
of inflammation such as IL-1 on either the protein or
mRNA level.
Conclusions
We found that cerebral inflammation measured by using
sVCAM-1 levels in the CSF was an independent risk fac-
tor for early death in AD. A more-advanced disease stage
was also a risk factor, as assessed by using the significantly
independent variables of global cognition and medial tem-
poral and frontal atrophy. The biomarkers of tau or amyl-
oid were not significant risk factors, and cerebrovascular
pathology was only a significant risk factor when including
death caused by vascular disorders and infections. This is
the first study of its kind, and further research is needed
to confirm these findings. As early death is linked to a
rapid disease progression [53], our results could have im-
plications for estimating the malignancy or toxicity of the
AD process, and for selecting correct targets in future
clinical trials of disease-modifying therapies.
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